44 results on '"Schnoy, Elisabeth"'
Search Results
2. Detection of duodenal villous atrophy on endoscopic images using a deep learning algorithm
3. An artificial intelligence algorithm is highly accurate for detecting endoscopic features of eosinophilic esophagitis
4. Influence of artificial intelligence on the diagnostic performance of endoscopists in the assessment of Barrett's esophagus: a tandem randomized and video trial.
5. Effect of AI on performance of endoscopists to detect Barrett neoplasia: A Randomized Tandem Trial
6. Überwachung und Management von Dysplasien bei chronisch-entzündlichen Darmerkrankungen
7. Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.
8. Morbus Crohn: Vielversprechende Behandlungsoption eines neuen IL-23-Inhibitors auf dem Weg zur Zulassung.
9. Update des Addendums zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch-entzündlichen Darmerkrankungen in Bezug auf COVID-19 (Version 2.0).
10. Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels
11. New therapies in inflammatory bowel disease: “nibs”, “mabs” and “mods”
12. S842 Pharmacokinetics, Exposure-Response Relationships, and Immunogenicity in Crohn’s Disease Patients With Ustekinumab Secondary Loss of Response Following Ustekinumab IV Re-Induction: Week 16 Results From the POWER Study
13. S1035 Analysis of Baseline Characteristics Associated With Clinical Response to Ustekinumab IV Re-Induction Strategy in Patients With Crohn’s Disease in the POWER Trial
14. Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels.
15. Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn’s Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study
16. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO study
17. Evaluation of a single-use gastroscope in patients presenting with suspected upper gastrointestinal hemorrhage: a pilot feasibility study (One-Scope I)
18. Wenn der Körper gegen sich selbst kämpft
19. Impact of Small Intestinal Bacterial Overgrowth in Patients with Inflammatory Bowel Disease and Other Gastrointestinal Disorders—A Retrospective Analysis in a Tertiary Single Center and Review of the Literature
20. Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects
21. Su1544: INTEGRATING THE PATIENT PERSPECTIVE TO VALIDATE A MEASURE OF DISEASE SEVERITY IN INFLAMMATORY BOWEL DISEASE
22. Su1515: EFFECT OF VEDOLIZUMAB ON HEALTH-RELATED QUALITY OF LIFE AND 1-YEAR EFFECTIVENESS IN COMPARISON TO ANTI-TNF THERAPY IN BIOLOGIC-NAÏVE CROHN'S DISEASE PATIENTS WITH PROPENSITY SCORE ADJUSTMENT: RESULTS OF THE VEDOIBD STUDY
23. Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis
24. Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis.
25. How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohort
26. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany
27. Underwater vs Conventional Endoscopic Mucosal Resection of Large Sessile or Flat Colorectal Polyps: A Prospective Randomized Controlled Trial
28. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
29. Colitis ulcerosa: Zur Behandlung einer Anämie ist die Wirksamkeit von Spirulina-Supplement noch nicht ausreichend belegt.
30. 1027 EFFICACY AND SAFETY OF INTRAVENOUS USTEKINUMAB REINDUCTION THERAPY IN CROHN'S DISEASE PATIENTS WITH SECONDARY LOSS OF RESPONSE TO USTEKINUMAB MAINTENANCE THERAPY: WEEK 16 RESULTS FROM THE POWER TRIAL
31. Su1825 QUALITY OF LIFE AND EFFECTIVENESS OF BIOLOGICS IN IBD-PATIENTS - AN INTERIM-ANALYSIS OF VEDOLIZUMAB AND OTHER BIOLOGICS IN A REAL WORLD SETTING IN GERMANY (VEDOIBD-STUDY)
32. Additional file 1: of Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects
33. Colitis ulcerosa: Zur Behandlung einer Anämie ist die Wirksamkeit von Spirulina-Supplement noch nicht ausreichend belegt
34. Suitability of the simplified autoimmune hepatitis score for the diagnosis of autoimmune hepatitis in a German cohort
35. Advanced Mucinous Colorectal Cancer: Epidemiology, Prognosis and Efficacy of Chemotherapeutic Treatment
36. Chemotherapy for metastatic colon cancer: Effect on survival when the dose is reduced due to side effects.
37. Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study
38. Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
39. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
40. Lapatinib versus lapatinib plus capecitabine as second-line treatment in HER-2-overexpressing metastatic gastro-esophageal cancer (GC): A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
41. Hemoglobin and Hematocrit Levels in the Prediction of Complicated Crohn's Disease Behavior – A Cohort Study
42. Integrating the Patient Perspective to Validate a Measure of Disease Severity in Inflammatory Bowel Disease: Online Survey of Patients and Their Physicians.
43. [Update: Addendum to S3-Guidelines Crohn disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease with regard to COVID-19 (version 2.0)].
44. Smoking increases the risk of extraintestinal manifestations in Crohn's disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.